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Abstract The field of prenatal genetic testing has
exploded with new non-invasive technologies and test
options in the past several years. It is challenging for
women’s healthcare providers to keep up with the multi-
tude of publications and provide patients with the most
accurate and up-to-date information possible regarding
prenatal testing. In this article, we examine the sequencing
technologies that provide the framework for non-invasive
prenatal testing (NIPT) and review the major North
American NIPT clinical validation studies published in
2011 and 2012. This paper also compares and contrasts the
commercially available non-invasive prenatal tests in the
United States, discusses clinical implementation recom-
mendations from professional societies and highlights
considerations for genetic counseling.
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Introduction
In 1959, Dr. Jerome Lejeune established trisomy 21 (three
copies of chromosome 21) as the cause of Down syndrome.
This was the first time that the etiology of a clinical dis-
order was found to be caused by a chromosome abnor-
mality. By 1960, trisomy 18 had been determined to be the
cause of Edwards syndrome and trisomy 13 the cause of
Patau syndrome. Since these findings, the clinical signifi-
cance of numerical chromosome aberrations has been well
established. In humans, approximately 10–30 % of fertil-
ized eggs have an incorrect number of chromosomes
(aneuploidy). An estimated one-third of all miscarriages
are aneuploid and one in every 300 liveborns is aneuploid.
As such, aneuploidy is the leading known genetic cause of
miscarriage and congenital birth defects [1, 2].
Pregnant women considered to be at high risk have been
offered prenatal diagnosis to detect chromosomal disorders
since the late 1960s. Amniocentesis and chorionic villus
sampling (CVS) are the most common methods available
for diagnostic testing; both of these are invasive procedures
and pose risks to the mother and fetus (most significantly a
risk of miscarriage of 1 in 200–400 and 1 in 100–200,
respectively) [3, 4]. More recently, one study reported a 1
in 1600 risk of miscarriage following amniocentesis [5].
While the actual procedure-related miscarriage rates are
debatable, most practitioners agree that there is some
inherent risk. Due to these risks, common practice is that
healthcare providers recommend the option of diagnostic
testing only to women at high risk of having a chromo-
somally abnormal fetus. Initially, determination of a high-
risk population was based on maternal age alone, and
hundreds of invasive procedures were performed to find
one affected fetus. Selection of such women has improved
over the years through a combination of measurement of
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maternal serum markers and most recently with the mea-
surement of fetal nuchal translucency (NT) by ultrasound.
Various screening tests to determine risk for fetal trisomy
21 are currently available including measurement of: NT
only, serum-only (in the first and/or second trimester) or
the combination of NT and serum markers. Using these
methods, detection rates vary from 70–94 % with false
positive rates of 1–5 % depending on the screen performed,
the gestational age at the time it is performed and maternal
age [6]. Most laboratories also provide screening results for
trisomy 18 and, less often, trisomy 13. Overall, these
methods are limited by their sub-optimal sensitivities and
specificities and often involve a multistep testing process
including an ultrasound measurement that can only be
performed at centers with certified sonographers.
For decades, researchers, physicians and pregnant
women alike have searched for a non-invasive way to
perform prenatal diagnosis. Ideally, such a non-invasive
prenatal test would replace amniocentesis and CVS or at
least minimize false positive results, thus significantly
reducing the number of women undergoing unnecessary,
risky invasive procedures [7].
The past several years have seen many exciting advan-
ces in the field of non-invasive prenatal testing (NIPT)
including the discovery of fetal cell-free DNA (cfDNA) in
maternal plasma and the development of massively parallel
sequencing (MPS) and counting techniques using cfDNA,
leading to the launch of the first non-invasive tests for fetal
aneuploidy. But, the work is not over yet. In October 2010,
a cfDNA testing survey was completed by 62 women’s
healthcare providers; 87 % of respondents were physicians
and 11 % were nurse practitioners, registered nurses or
certified nurse-midwives. A significant finding from this
survey was only 15 % of participants reported having a
‘‘high level of knowledge’’ about NIPT [8]. In December
2012, the American College of Obstetricians and Gyne-
cologists issued a joint committee opinion with the Society
of Maternal Fetal Medicine supporting the use of NIPT in
clinical practice for high-risk women [9••]. It is now the
responsibility of women’s healthcare providers to become
more educated about NIPT.
The aim of this paper, therefore, is to inform women’s
healthcare providers about the principles of NIPT so they
may determine if and when it is right for their patients and
how to counsel these women both before and after under-
going NIPT.
Properties of Fetal Cell-Free Nucleic Acids
The existence of cfDNA in blood was first discovered in
1947 [10]. This cfDNA is present in small fragments of
150–200 base pairs in length [11, 12]. These fragments are
most likely degraded nuclear DNA from cells that have
undergone programmed cell death (also known as cellular
apoptosis) [13, 14•], although other hypotheses for the
origin of cfDNA (such as spontaneous release by living
cells) have also been proposed [15, 16]. Despite the elu-
siveness of the cfDNA origin, analyzing the cfDNA for
diagnostic purposes was first motivated by the finding of
tumor-derived cfDNA in cancer patients [17, 18]. The
subsequent discovery in 1997 of cfDNA fragments of fetal
Y-chromosomes in the plasma of pregnant women with
male fetuses opened the door for the development of NIPT
using maternal blood [19].
Studies summarized in the reviews by Bianchi [20]
and Edlow and Bianchi [21•] suggest that the majority of
fetal cfDNA in maternal plasma is derived from the
placenta, with minor contributions from the fetal hema-
topoietic system and the fetus itself. Fetal cfDNA can be
reliably detected in the maternal circulation by 7 weeks
gestation and its amount increases with gestational age.
The portion of fetal cfDNA is called the fetal fraction.
The fetal fraction varies among pregnant individuals but
has been shown to be 10 % on average (ranging from 3
to 19 %) [22, 23]. One study suggested that fetal cfDNA
has an average half-life of 16.3 min (ranging from 4 to
30 min) and is cleared rapidly post-delivery such that
levels are undetectable by a few hours post-partum [24].
All of these properties make fetal cfDNA an ideal can-
didate for NIPT.
Early clinical applications of fetal cfDNA for prenatal
testing included fetal RhD genotyping [25] and sex
determination to aid in the risk assessment of X-linked
disorders and congenital adrenal hyperplasia (CAH) uti-
lizing the detection of Y-chromosomes in the plasma of
women pregnant with male fetuses [26]. The initial suc-
cess in fetal RhD genotyping and fetal sex determination
demonstrated the utility of fetal cfDNA in NIPT and
encouraged the research and development of other non-
invasive assays for monogenetic disorders, such as thal-
assemia, Huntington disease, cystic fibrosis, and myotonic
dystrophy [21•]. However, most of the developed assays
are PCR-based and thus are limited by PCR primer
specificity and assay sensitivity. Also, given that most
cfDNA in circulation is maternal in origin and there is
over 99 % homology between maternal and fetal DNA, it
is difficult to use the traditional PCR technology for fetal
aneuploidy detection. Therefore, a novel approach for
developing NIPT to detect fetal aneuploidy was still
needed. The recent advancements in DNA sequencing
technology, as well as counting statistics, have provided a
timely opportunity to develop new methods for the non-
invasive detection of fetal aneuploidy.
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Sequencing Methodologies and Bioinformatic
Analytical Approaches
In 2008, Fan et al. [14•] published a revolutionary paper
describing a quantification method for non-invasive fetal
aneuploidy detection involving counting chromosomes
by mapping sequence tags generated via MPS of cfDNA
in maternal plasma, even without separating maternal
and fetal cfDNA or enriching for fetal cfDNA. More
specifically, this method generates tens of millions of
sequence reads across the entire genome that can be
aligned and uniquely mapped (tagged) to sites from a
reference human genome to identify their chromosome
of origin. Once mapped, the tags can be counted for
determination of the chromosome ploidy status (see
Fig. 1). The ability to count millions of tags allows for
very high sensitivity to detect aneuploidy in a given
sample. When aneuploidy is present, there is an increase
(trisomy) or decrease (monosomy) in the relative number
of tags on the affected chromosome compared to the
euploid chromosomes.
Ehrich et al. [27] and Chiu et al. [28] published addi-
tional studies on the performance of the above method for
the detection of trisomy 21. As noted in their papers, the
counting and normalization algorithms used in these stud-
ies using a z-score were unable to effectively detect other
aneuploidies. This is likely due to technical and sample-to-
sample sequencing variations in the chromosomal distri-
bution of sequence reads as has been discussed in many
papers [14•, 29•, 30]. Sehnert et al. [31•] and Bianchi et al.
[32] developed and tested an optimized counting algorithm
and demonstrated its ability to detect multiple chromosome
abnormalities (e.g., trisomies 21, 18, 13, monosomy X,
trisomy 20, trisomy 16) in two independent studies. Their
optimized algorithm utilizes normalized chromosome val-
ues (NCVs), where the count of mapped tags for a given
chromosome of interest is normalized to cumulative counts
observed on a predetermined set of optimal (‘‘reference’’)
chromosomes. This approach helps to correct for technical
and sample-to-sample sequencing variations and mitigates
the need to perform additional corrections on the data (e.g.,
correction for guanine–cytosine (GC) content) [7, 31•].
Subsequent studies by several groups have shown that
trisomies 18 and 13 can also be detected by applying a GC
adjustment to the z-score algorithm to help correct for
variations in sequencing reads [29•, 30, 33].
Utilizing concepts that are similar to those developed by
Fan et al. [14•], a second MPS counting approach
sequencing only a limited number of cfDNA fragments has
also been tested for non-invasive aneuploidy detection.
This ‘‘targeted sequencing’’ approach has been demon-
strated for chromosomes 21, 18 and 13 only [34–37].
Clinical Validation Studies of NIPT
Three large-scale clinical validation studies originating in
North America were performed from 2009 to 2011, and the
results from these studies were reported in four recent
publications [32, 33, 36, 38]. The following is an analysis
of the study aspects we found to be of particular relevance
to practicing clinicians: study design (sample and data
collection, analysis plans) and measures of test perfor-
mance (including test failures), as these directly correlate
to clinical implementation of NIPT.
Sample and Data Collection
All studies had multicenter participation and involved
collection of blood from pregnant women who were
undergoing invasive prenatal procedures (CVS or amnio-
centesis). Blood was drawn prior to performance of the
procedures in all cases. Conventional cytogenetic karyo-
type from CVS or amniocentesis was used as the reference
standard in all studies. Fluorescence in situ hybridization
(FISH) or quantitative fluorescent polymerase chain reac-
tion (QF-PCR) results from CVS/amniocentesis or on the
products of conception were used as the reference standard
in the few cases where a conventional metaphase karyotype
was not available. To be eligible for the studies by
Palomaki et al. [38] and Bianchi et al. [32], women were
included if they were ‘‘high-risk’’ as defined by advanced
maternal age, having a positive prenatal serum screen
result, presence of an ultrasound finding suggestive of fetal
aneuploidy and/or a history of aneuploidy. Norton et al.
[36] accepted samples from any pregnant woman under-
going an invasive procedure. However, the sample size
determinations, incidence of aneuploidy and participant
demographics for that study indicate that the majority of
their participants were also ‘‘high-risk’’.
Analysis Plans
Palomaki et al. [33, 38] and Bianchi et al. [32] used a
blinded nested case–control approach while Norton et al.
[36] was a cohort study that also used case–control analysis
for determining test performance. All samples analyzed
were from women with singleton pregnancies.
In the Palomaki et al. and Norton et al. studies, cases
were the affected trisomy of interest (e.g., trisomy 21) and
the controls were euploid samples only. Palomaki et al.
[33, 38] did this first by analyzing the performance for
trisomy 21 and subsequently analyzing trisomy 18 and
trisomy 13 performance in a case–control analysis from the
same initial cohort (along with reassessing the performance
for trisomy 21 using a modified bioinformatics algorithm).
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Translocation trisomies and mosaics were not included in
Palomaki et al., study. Norton et al., did independent case–
control analyses for trisomies 21 and 18. They did not
exclude cases of translocation trisomy but did exclude
cases of mosaicism [36].
Bianchi et al., is the only study to simultaneously assess
the performance of their NIPT for six independent cate-
gories in each eligible sample: trisomy 21, trisomy 18,
trisomy 13, monosomy X and sex determination (XX or
XY). In addition, since they included all samples with any
abnormal karyotype and analyzed all chromosomes across
the genome in the analyzed dataset, they also reported
NIPT results for a variety of other chromosome abnor-
malities (e.g., trisomy 20) [32]. As a result of their study
design, cases of translocation trisomy were included; cases
with mosaicism were also sequenced but these were not
included in the performance calculations. Controls for each
analysis in this study were all of the analyzed samples that
did not have the aneuploidy of interest. As such, the same
sample with trisomy 21 could be counted as a ‘‘case’’ in
one analysis and a ‘‘control’’ in another analysis.
Sample size requirements were determined prior to initia-
tion of the studies. All of the studies were powered to include
the number of trisomy 21 cases needed to achieve statistical
significance at a high level of performance (sensitivity and
specificity), approaching that of diagnostic tests such as CVS
and amniocentesis which have sensitivities of 99.25 and
99.4 % and specificities of 98.65 and 99.5 %, respectively [3,
39]. Assumptions were based upon early, proof-of-principle
studies anticipating that NIPT performance would meet or
exceed prenatal screening tests as their goal.
Test Performance
Trisomy and absence of trisomy were categorized as
‘‘consistent with trisomy’’ and ‘‘normal’’ in the Palomaki
Fig. 1 Massively parallel
sequencing and counting for the
detection of fetal aneuploidy.
cfDNA is isolated from
maternal plasma. The total
cfDNA is sequenced by MPS,
generating millions of sequence
reads. Sequence reads are then
aligned to sites from a reference
human genome and the aligned
reads (tags) are counted for
determination of the
chromosome ploidy status
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et al., studies, ‘‘affected’’ and ‘‘unaffected’’ in the Bianchi
et al., study, and ‘‘high-risk’’ (risk score of C1 %) and
‘‘low-risk’’ (risk score \1 %) in the Norton et al., study
[32, 33, 36, 38]. The sensitivities and specificities of NIPT
for trisomy 21 and trisomy 18 are shown in Table 1. The
sensitivities and specificities of NIPT for trisomy 13 are
also shown in Table 1 for the Bianchi et al., and Palomaki
et al., studies.
It should be noted that Ashoor et al., also recently
developed and optimized an algorithm for non-invasive
trisomy 13 detection. The study design was significantly
different than the aforementioned studies. Therefore, the
data are not included in Table 1. This was a case–control
study of ten cases of trisomy 13 (confirmed by CVS/
amniocentesis) and 1,992 presumed euploid controls from
a single site in the United Kingdom. They reported a cal-
culated sensitivity of 80 % (95 % CI 48–94.9 %) and a
specificity of 99.95 % (95 % CI 99.7–100 %) [37].
Results were not generated in any of the studies if the
measured fetal fraction did not meet a certain threshold or
if the assay failed at any step of the process. Test failure
rates were reported by Palomaki et al. [33], Bianchi et al.
[32] and Norton et al. [36] as 5.3, 3, and 4.6 %, respec-
tively. Palomaki et al., was the only study to reflex to a
second sample if the initial sample failed. They were able
to reduce the number of test failures to 0.9 % if a second
sample was tested [33]. It should be noted that Bianchi
et al., categorized certain samples as ‘‘unclassified’’. These
samples were not included in the test failure rates as the
assay provided a result, albeit an intermediate one [32].
All of the studies achieved high performance as seen by
the sensitivity and specificity calculations (see Table 1).
Based on the number of samples tested, the highest degree
of confidence is seen for trisomy 21, followed by trisomy
18. Performance for chromosome 13 is impacted by
smaller sample sizes and thus wider 95 % confidence
intervals making it more difficult to draw conclusions.
Commercially Available Tests in the United States
The highly successful results from the aforementioned
clinical validation studies led to the recent launch of three
commercially available non-invasive prenatal tests in the
United States. Table 2 highlights the test similarities and
differences in terms of which chromosomes are tested,
sample acceptability criteria, and the timeframe in which
results are returned.
These tests are rapidly evolving and additional labora-
tories are predicted to offer non-invasive prenatal tests in
the near future. As such, women’s healthcare providers are
encouraged to contact the various laboratories to confirm
the details of the tests prior to ordering. Several insurance
plans have published coverage decisions that are now
effective for all commercially-available NIPTs. Once
individual laboratories offering NIPT sign test-specific
contracts with insurance plans, their particular test will
then be in-network and covered. This will mean lower out-
of-pocket costs for many patients.
Clinical Implementation
Providers can look to several professional societies for
guidance on how to implement the new non-invasive tests
for fetal aneuploidy into their practices. The International
Society for Prenatal Diagnosis (ISPD), the National Soci-
ety of Genetic Counselors (NSGC), the American College
of Obstetricians and Gynecologists (ACOG) and the
Society for Maternal Fetal Medicine (SMFM) have all
commented on the use of NIPT in clinical practice [9••, 40,
41••]. In reviewing the various societal statements on
NIPT, we identified three important themes that we feel are
worthy of discussion.
1. There are several clinical indications for which NIPT
should be considered.
After reviewing the published data on NIPT, the afore-
mentioned professional societies have unanimously agreed
that NIPT is a safe and effective screening test for fetal
aneuploidy in high-risk women. It can be used as a primary
screen for women at high-risk based on their age, the
presence of ultrasound anomalies, a history of aneuploidy
and in those pregnancies at risk for aneuploidy due to the
presence of a Robertsonian translocation in a parent. NIPT
can also be used as a follow-up test for those women who
have a positive first and/or second trimester screen.
None of the societies support the use of non-invasive
prenatal tests in the low/average risk populations at this
time due to the lack of data. Furthermore, ACOG does not
support its use in multi-fetal gestations.
2. NIPT is an advanced screening tool and confirmation of
positives through CVS/amniocentesis is currently necessary.
Given the high sensitivity of NIPT, patients with negative
NIPT results should be counseled that the chance of aneu-
ploidy for the chromosomes tested is low. However, a
negative result does not completely rule out the possibility
of trisomies 21, 18 and 13 and NIPT results should be used
in the context of all relevant clinical information. Further-
more, NIPT does not currently test for all aneuploidies, nor
does it provide information on polyploidy and single-gene
disorders. As such, patients should continue to be given the
option of diagnostic testing (CVS or amniocentesis), espe-
cially in cases of an ultrasound-identified fetal structural
abnormality or a family history of a genetic condition.
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Positive NIPT results are typically associated with an
affected fetus. However, there will be instances where a
patient has a positive NIPT result and a normal CVS/
amniocentesis result. Therefore, patients receiving a positive
result should be counseled about the importance of con-
firming the result via CVS or amniocentesis, especially prior
to making irreversible pregnancy management decisions.
Clinicians will encounter situations where patients have
a positive NIPT result and decline confirmatory testing. For
patients who decline invasive testing and continue the
pregnancy, confirmation of a positive NIPT result can be
done postnatally. If after counseling, a patient chooses to
decline confirmatory CVS/amniocentesis and proceeds
with termination of the pregnancy, chromosome analysis
should be performed on the products of conception. Not
only will this allow for confirmation of the NIPT result, it
will assist with determination of recurrence risks as NIPT
does not distinguish non-disjunction trisomy from trans-
location trisomy.
When a positive result from NIPT is inconsistent with a
CVS or amniocentesis karyotype, several biological expla-
nations for such discordant results should be considered. For
example, as it has been hypothesized that fetal cfDNA origi-
nates from placental cytotrophoblasts [42, 43], it is possible
that the NIPT result detected confined placental mosaicism
(CPM). Also, given that NIPT analyzes total cfDNA (mater-
nal and fetal), a positive NIPT finding may in fact be detecting
maternal aneuploidy, full or mosaic. Other biological expla-
nations include low-level fetal mosaicism that is undetectable
by routine cytogenetics and the presence of fetal cell-free
DNA from a demised/vanishing co-twin [7]. Additionally,
there will be a very small percentage of positive NIPT results
that are falsely positive due to the technology itself.
3. It is crucial that patients make informed choices about
undergoing NIPT.
Informed choice is a process that stems from the bio-
ethical principle of respect for autonomy. Informed choice
Table 1 Patient demographics and NIPT performance statistics
Palomaki et al. [38] Palomaki et al. [33] Bianchi et al. [32] Norton et al. [36]
Subjects enrolled (N) 4,664 4,664 2,882 4,002
Analyzed samples (N) 1,696 1,988* 532 3,007
Trisomy 21 cases (N) 212 212 89 81
Trisomy 18 cases (N) 59 36 38
Trisomy 13 cases (N) 12 14
Monosomy X Cases (N) 16
Female Cases (N) 233
Male Cases (N) 184
Maternal age cases and controls (years) mean ± SD 37 ± 5 36.6 ± 4.9 T18 34.4 ± 6.73 35.4 ± 7.3 T21
36.6 ± 5.1 33.3 ± 5.6 T13 35.2 ± 6.40 34.5 ± 6.1 T18
37.6 ± 5 eupld 34.3 ± 6.3 eupld
Gestational age mean cases and controls (weeks) 15.3 14.8 T18 14.8 16.4 T21
15.0 15.2 T13 15.1 16.2 T18
14.7 eupld 17.0 eupld
Trisomy 21 sensitivity (%) 98.6 (95.9–99.7) 99.1 (96.6–99.9) 100 (95.9–100) 100 (95.5–100)
Trisomy 21 specificity (%) 99.8 (99.4–99.9) 99.9 (99.7–99.9) 100 (99.1–100) 99.97 (99.8–99.99)
Trisomy 18 sensitivity (%) 100 (93.9–100) 97.2 (85.5–99.9) 97.4 (86.5–99.9)
Trisomy 18 specificity (%) 99.7 (99.3–99.9) 100 (99.2–100) 99.93 (99.75–99.98)
Trisomy 13 sensitivity (%) 91.7 (61–99) 78.6 (49.2–99.9)
Trisomy 13 specificity (%) 99.1 (98.5–99.5) 100 (99.2–100)
Female sensitivity (%) 99 (97.6–99.9)
Female specificity (%) 99.5 (97.2–99.9)
Male sensitivity (%) 100 (98–100)
Male specificity (%) 100 (98.5–100)
MX sensitivity (%) 93.8 (69.8–99.8)
MX specificity (%) 99.8 (98.7–99.9)
Numbers in parentheses are 95% confidence intervals given as %, SD standard deviation, CI confidence interval, eupld euploid, MX monosomy X
* 1695 of these samples were re-tested from original study [38]
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implies that patients are given adequate information about
the risks and benefits of a procedure and are free to make
choices about the procedure based on the information pro-
vided and their own personal values and beliefs [44, 45••]. It
is common practice that high-risk pregnant women who are
considering amniocentesis or CVS undergo an informed
choice process with a genetic counselor as these procedures
are associated with maternal and fetal risks and provide
definitive information about certain medical conditions. It is
also common practice that pregnant women considering
aneuploidy screening tests simply receive pretest informa-
tion (usually minimal) from their primary provider, and
only meet with a genetic counselor if their screening result
is positive [45••]. Since NIPT does not pose a physical risk
to the mother or her fetus, some healthcare providers
question whether patients need to make informed choices
prior to undergoing such testing [46].
Even though NIPT is not risky like CVS and amniocente-
sis, the implications of a positive NIPT result are significant.
Given the high specificity of NIPT, most women who receive
a positive result will have essentially received a prenatal
diagnosis of aneuploidy. This is much different than con-
ventional screening tests which have a significant false posi-
tive rate, affording women time to decide whether they truly
want to know certain information about their fetus’s health
prenatally. Therefore, giving patients minimal information
prior to such tests, as is done with current aneuploidy screens,
would according to Benn and Chapman, ‘‘[B]e a much more
seriously deficient medical practice, undermining patient
autonomy and reproductive decision-making’’ [45••].
Future Directions
In the past 5–10 years, we have seen the clinical introduction
of NIPT for RhD status, the determination of fetal sex to aid
in the assessment for sex-linked conditions, and certain fetal
aneuploidies. The utility of MPS of cfDNA is currently being
evaluated for multi-fetal gestations as well as for average-
risk pregnant women. This is incredibly exciting, but what is
perhaps most exciting is the very real possibility that the
MPS of cfDNA technique will be clinically available and
effective for all fetal aneuploidies, sub-chromosomal dele-
tions and duplications, monogenic disorders and eventually
the entire fetal genome. Furthermore, there is promising
research in the field of using quantitative cfDNA testing as a
biomarker to provide early diagnosis of preeclampsia and
other pregnancy complications [47, 48]. This suggests that
analysis of cfDNA may be able to predict maternal, as well as
fetal, well-being during pregnancy.
Conclusion
Cumulative evidence suggests that NIPT using MPS can be
safely introduced into existing prenatal screening algo-
rithms to reduce unnecessary invasive procedures. Guide-
lines from several professional societies now exist to aid
women’s healthcare providers in determining under which
circumstances patients should be offered such testing. In
turn, it is now the responsibility of the providers to dif-
ferentiate between the clinically available non-invasive
prenatal tests, select the most efficacious NIPT for their
patient population and ensure that pre- and post-test genetic
counseling is effectively provided.
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Table 2 Comparison of commercially-available NIPTs
Sequenom CMM Verinata Health, an Illumina company AriosaTM
Diagnostics
Chromosomes tested 21, 18, 13, XX, XY, MX, XXY,
XXX, XYY
21, 18, 13
XXX, XXY, XYY, MX, X & Y are optional
21, 18, 13
Results reported as Positive Aneuploidy detected High-risk (C1 %)*
Negative No aneuploidy detected Low-risk (\1 %)*
Aneuploidy suspected/borderline value
Gestational age at which test
can be performed (weeks)
10? 10? 10?
Samples accepted for multi-
fetal gestations
Yes No No
Samples accepted for egg
donor/surrogate pregnancies
Yes Yes No
Turn-around time 8–10 days 8–10 days 8–10 days
* Risk score included
MX monosomy X
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distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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